Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,046.91
-4.33 (-0.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
40
41
Next >
Adagio Therapeutics Continues Its Wild Ride — How Two Tests Led To A Triple-Digit Gain
December 16, 2021
Two tests from independent labs suggest Adagio's antibody could still target omicron.
Via
Investor's Business Daily
AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant
December 16, 2021
New preclinical data released by AstraZeneca Plc (NASDAQ: AZN) shows that its long-acting antibody Evusheld (tixagevimab co-packaged with cilgavimab) works against...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:
Via
Benzinga
Biotech Playbook 2021: No Help From Small Caps In Q4
December 14, 2021
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but...
Via
Talk Markets
Composite Rating For Regeneron Stock Rises To 96
December 09, 2021
Regeneron stock saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 93 the day before for the New York firm.
Via
Investor's Business Daily
Novartis Reveals Two Year Results From Beovu Trial In Diabetic Macular Edema Patients
December 09, 2021
Novartis AG (NYSE: NVS) has reported the first interpretable results from year two (week 100) of the Phase 3 KESTREL study of Beovu (brolucizumab) 6 mg in patients...
Via
Benzinga
4 Low-Beta Stocks To Buy For A Volatile Market
December 08, 2021
Global economic uncertainty, inflationary pressure, a disappointing jobs report, and concerns around the COVID-19 Omicron variant are fostering market volatility. So, against this backdrop, we think it...
Via
Talk Markets
Exposures
COVID-19
2 Big Stock Bets That Are Insiders Are Buying Now
December 06, 2021
Reddit users picked their favorite biotech stocks, and all of them have fallen this year. The insiders have a different buying strategy.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
December 09, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:
Via
Benzinga
How Did Healthcare Stocks Perform Over This Volatile Month?
December 06, 2021
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%.
Via
Talk Markets
Where Regeneron Pharmaceuticals Stands With Analysts
December 06, 2021
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
December 06, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX:
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Stock Market Rally Hammered On Hawkish Fed, Omicron Fears; Salesforce, Snowflake, DocuSign, Xpeng In Focus: Weekly Review
December 03, 2021
Stocks suffered sharp losses, amid omicron fears and a more-hawkish Fed.
Via
Investor's Business Daily
Topics
Bonds
Economy
Stocks
Exposures
Debt Markets
Fossil Fuels
Interest Rates
The 'Highly Mutated Virus' Signals A Need For Annual Shots: BioNTech CEO
December 03, 2021
The omicron variant signals a need for annual Covid shots, BioNTech's CEO said.
Via
Investor's Business Daily
Regeneron: Surfing on Covid, With More Under the Surface
December 02, 2021
Regeneron has a method for finding blockbuster drugs, like the Covid drug that powered 2021 REGN stock results, but there's even more to come.
Via
InvestorPlace
Exposures
COVID-19
Why Are Stocks Down Today? 4 Things to Know.
November 30, 2021
Why are stocks down today? It seems that fears over tapering, inflation and the omicron variant are worrying investors on Tuesday.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
HC Wainwright Sees 'Buying Opportunity' For This COVID-19 Antibody Stock After Sell-Off
November 30, 2021
H.C. Wainwright recommends using the selloff today for Regeneron Pharmaceuticals Inc (NASDAQ:
Via
Benzinga
Exposures
COVID-19
7 Drug Stocks to Buy Now While They’re Still on Sale
November 30, 2021
Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead.
Via
InvestorPlace
Topics
Supply Chain
Exposures
COVID-19
Supply Chain
Adagio Continues Its Run As Biotech Stocks Moderna, BioNTech Dive On Omicron Threat
November 30, 2021
Biotech stocks diverged Tuesday with Adagio continuing a run on the potential for its antibody to target Covid's omicron variant.
Via
Investor's Business Daily
Retail Stocks Trading Lower on Weaker Black Friday Numbers
November 30, 2021
After Friday’s Omicron variant sell-off, things were looking pretty bleak for investors, but stocks rallied back on Monday. The Nasdaq Composite (COMP:GIDS) led...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
November 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-...
Via
Benzinga
Exposures
Product Safety
Increased Prevalence of Atopic Dermatitis Fueling Impressive Growth for Atopic Dermatitis Drugs
November 30, 2021
Palm Beach, FL –November 30, 2021 – FinancialNewsMedia.com News Commentary – Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White...
Via
FinancialNewsMedia
ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential
November 29, 2021
Shares of ADGI stock are soaring higher by 80% after the company stated that its ADG-20 antibody is effective against the omicron variant.
Via
InvestorPlace
Exposures
COVID-19
Adagio shares soar on antibody potential against new COVID variant omicron
November 29, 2021
Stifel analyst Stephen Willey believes vaccines alone are unlikely to sufficiently address the COVID-19 pandemic.
Via
Talk Markets
Exposures
COVID-19
3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries
November 29, 2021
The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a h...
Via
Benzinga
Exposures
COVID-19
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
November 29, 2021
Smaller companies are working on next-generation approaches to Covid treatment.
Via
Investor's Business Daily
Biotech Stocks are Due for a Rally
November 22, 2021
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums.
Via
Talk Markets
Regeneron Extends Hearing Loss Gene Therapy pact With Decibel
November 22, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover...
Via
Benzinga
Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much
November 20, 2021
The therapy will likely face stiff competition from more convenient COVID-19 pills.
Via
The Motley Fool
Exposures
COVID-19
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.